Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma
暂无分享,去创建一个
A. Branch | R. Dhanasekaran | C. Murphy | A. Duarte-Rojo | G. Ioannou | A. Singal | R. Wong | L. Kulik | J. Feld | H. Samant | M. Leise | N. Parikh | Janice H. Jou | T. Tran | A. Said | A. Rangnekar | P. Jalal | P. Gopal | C. Frenette | S. Satapathy | K. Bhamidimarri | A. Pillai | M. Hoteit | N. Rich | N. Mehta | R. Salgia | Omobonike O. Oloruntoba | S. Eswaran | S. Scaglione | P. Mantry | B. John | Avegail Flores | M. Odewole | S. Kagan | J. Guy | M. Volk | A. Huang | Binu V. John
[1] A. Singal,et al. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. , 2019, Gastroenterology.
[2] J. Bruix,et al. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. , 2019, Journal of hepatology.
[3] A. Branch,et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. , 2019, Gastroenterology.
[4] Yu Shen,et al. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] H. El‐Serag,et al. Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.
[6] Giovanni Raimondo,et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.
[7] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.
[8] G. Cabibbo,et al. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[9] A. Singal,et al. Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy , 2018, Alimentary pharmacology & therapeutics.
[10] Kathleen A Cronin,et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.
[11] G. Heinze,et al. An unjustified benefit: immortal time bias in the analysis of time‐dependent events , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[12] G. Dore,et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.
[13] X. Forns,et al. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. , 2017, Gastroenterology.
[14] P. Maisonneuve,et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus‐related cirrhosis who attained sustained virological response , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[15] C. Nam,et al. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study , 2017, BMC Medical Research Methodology.
[16] G. Cabibbo,et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study , 2017, Alimentary pharmacology & therapeutics.
[17] G. Ioannou,et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. , 2017, Journal of hepatology.
[18] A. Gasbarrini,et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. , 2017, Journal of hepatology.
[19] D. Goldberg,et al. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. , 2017, Gastroenterology.
[20] R. Salem,et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. , 2017, Journal of hepatology.
[21] J. Bruix,et al. Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? , 2017, Seminars in Liver Disease.
[22] M. Ziol,et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.
[23] G. Ioannou,et al. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.
[24] Rafael Stern,et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. , 2016, Journal of hepatology.
[25] S. Pol. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.
[26] M. Makuuchi,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.
[27] M. Schwartz,et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. , 2015, Annals of surgery.
[28] Ashley L. Buchanan,et al. Worth the weight: using inverse probability weighted Cox models in AIDS research. , 2014, AIDS research and human retroviruses.
[29] Amit G. Singal,et al. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis , 2014, PLoS medicine.
[30] L. Bolondi,et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? , 2013, Journal of vascular and interventional radiology : JVIR.
[31] J. Marrero,et al. Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome , 2013, Annals of Surgical Oncology.
[32] S. Altekruse,et al. Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992‐2008 , 2012, Hepatology.
[33] Ryosuke Tateishi,et al. nature publishing group ORIGINAL CONTRIBUTIONS 569 CME Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors LIVER , 2022 .
[34] M. Puhan,et al. Systematic review and meta‐analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis , 2009, The British journal of surgery.
[35] Stephen R Cole,et al. Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.